CURRENT DIVERSIFICATION IN THE SELECTION OF MOLECULE(s)  FOR THE TREATMENT OF HYPERTENSION

Ahmed Ayedur  Rahman; Md. Mustafizur  Rahman

doi:10.53808/KUS.2005.6.1and2.0410-L

Authors

Ahmed Ayedur Rahman Pharmacy Discipline, Life Science School, Khulna University, Khulna 9208, Bangladesh
Md. Mustafizur Rahman Pharmacy Discipline, Life Science School, Khulna University, Khulna 9208, Bangladesh

DOI:

https://doi.org/10.53808/KUS.2005.6.1and2.0410-L

Keywords:

Antihypertensive, hypertension

Abstract

The study was carried out on the current diversification of antihypertensive drugs prescribed for the treatment of hypertensive patients irrespective of age and sex in the Government Hospitals of Khulna city, Bangladesh. The study covered only the indoor hypertensive patients. The frequency of hypertension was found maximum with patients above 40 years of age. The study showed that the prevalence of hypertension was more common in females compared to males. Among the therapeutic classes, Calcium channel blockers (CCB) were used most frequently (27%). Diuretics (25%) and Beta-blocker (24%) fell in the 2^nd and 3^rd position respectively. ACE inhibitors (18%) were also used frequently, but angiotensin-II antagonist, alpha-blocker and centrally acting antihypertensive drugs were used only in limited cases. Both combination therapy (57%) and monotherapy (43%) were used for the management of hypertension. Among the combinations, diuretics and ACE inhibitors combination was prescribed in most cases (20%). There was no combination of two or more molecules under the same therapeutic class. In case of mono-drug therapy metoprolol was used most frequently (25%) which was followed by amlodipine (20%) and nifedipine (18%). When individual drug molecules irrespective of their use either in combination or as single drug were taken into account, it was found that furosemide was most frequently (21%) used. Amlodipine (16%), nifedipine and atenolol (13%) followed furosemide.

Downloads

Download data is not yet available.

References

Andersson, O.K. 1998. Survival in treated hypertension: follow up study after two decades. British Medical Journal, 317: 167–171.

Annon, 2005. International Medicine Statistics, Vol. 3rd Quarter. IMS AG Cham, Switzerland, p. 2.

Clausen, J. and Jenson, G. 1992. Blood pressure and mortality: an epidemiological survey with 10 years follow-up. Journal of Human Hypertension, 6: 53–59.

Collins, R. 1990. Blood pressure, stroke, and coronary heart disease. Part 2, short-term reductions in blood pressure: overview of randomised drug trials in their epidemiological context. Lancet, 335: 827-838

Isles, C.G. 1986. Mortality in patients of the Glasgow blood pressure clinic. Journal of Hypertension, 4: 141–156.

Lwanga, S.K. and Lemeshow, S. 1991. Sample Size Determination in Health Studies. WHO Geneva.

Merlo, J. 1996. Incidence of myocardial infarction in elderly men being treated with antihypertensive drugs: population based cohort study. British Medical Journal, 313: 457– 461.

Ramsay, L.E.; Williams, B.; Johnston, G.D.; MacGregor, G.A.; Poston, L.; Potter, J.F.; Poulterand, N.R. and Russell, G. 1999. BHS Guidelines. Guidelines for management of hypertension, Report of the third working party of the British Hypertension Society. Journal of Human Hypertension, 13: 569–592

Thurmer, H.L.; Lund-Larsen, P.G. and Tverdal, A. 1994. Is blood pressure treatment as effective in a population setting Guidelines for management of hypertension British Hypertension Society 588 as in controlled trials? Results from a prospective study. Journal of Hypertension, 12: 481–490.

Walker, R. and Edwards, C. 2000. Clinical Pharmacy and Therapeutics. 2nd edn., pp. 247-259.